Verona Pharma :
VRNA
VRNA
Stock Data
$106.91
$0.00 (0.00%)
Asset Type
N/A
Exchange
N/A
Currency
N/A
Country
N/A
Sector
N/A
Industry
N/A
Verona Pharma Plc is a London-based biopharmaceutical company focused on creating treatments for respiratory diseases lacking adequate therapies. Its leading product, ensifentrine, is a novel compound with dual action as a bronchodilator and anti-inflammatory agent, currently in Phase 3 trials for conditions like chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Verona Pharma is exploring ensifentrine in various forms, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, aiming to meet critical healthcare needs.
All Verona Pharma Articles
7 Articles